---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-023667"
form_type: "8-K"
ticker: "RAPH"
cik: "0001415397"
company_name: "Raphael Pharmaceutical Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:32:20.809697+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Israeli Ministry of Health approves Raphael Pharma's Phase IIa COVID-19 trial for cannabis-based drug

## Summary
- Israeli Ministry of Health approved Raphael Pharmaceutical's application to commence a Phase IIa clinical trial in COVID-19 patients.
- The trial protocol was approved by the Helsinki Committee at Rambam Hospital on December 8, 2022.
- The trial involves a cannabis-based drug aimed at mitigating deterioration in COVID-19 patients.

## SEC filing metadata
- accession: 0001213900-23-023667
- form_type: 8-K
- ticker: RAPH
- cik: 0001415397
- company_name: Raphael Pharmaceutical Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1415397/000121390023023667/0001213900-23-023667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1415397/000121390023023667/ea175896-8k_raphael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-023667
- JSON: https://secwatch.observer/filing/0001213900-23-023667.json
- Plain text: https://secwatch.observer/filing/0001213900-23-023667.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.